Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses the next treatment steps for a patient with HER2-negative chemotherapy-resistant metastatic breast cancer.
Ragene Rivera, MD
Advertisement
Articles by Ragene Rivera, MD
Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.
Advertisement
Latest Updated Articles
Deciding Between Hormone Therapies in Patients With ER+/PR+ TumorsPublished: August 12th 2014 | Updated:
Treating a Patient With HER2-Negative Chemotherapy-Resistant mBCPublished: August 13th 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
